Cairo - Mubasher: Egyptian International Pharmaceutical Industries (EIPICO) posted on Wednesday a rise of 28.3% in its consolidated net profits for the first quarter of fiscal year 2017 to EGP 157.8 million, compared to EGP 123.01 million for Q1-16.
Consolidated sales increased in Q1-17 to EGP 605.5 million from EGP 495.8 million in Q1-16, according to a bourse filing.
General and administrative expenses declined in Q1-17 by 19.6% to EGP 14.8 million, compared to EGP 18.4 million in Q1-16.
Standalone net profit for Q1-17 amounted to EGP 150.5 million, versus EGP 116.6 million for Q1-16.
The stock fell on Tuesday by 0.035% to EGP 103.
